TM-25659

Cat. No. :	HY-112920
M.Wt:	500.60
Formula:	C30H28N8
Purity:	>98 %
Solubility:	DMSO : ≥ 135 mg/mL

Introduction of 260553-97-7 :

TM-25659 is a transcriptional co-activator with PDZ-binding motif (TAZ) modulator. Anti-osteoporotic and anti-obesity activities^[1]. IC50 & Target: TAZ^[1] In Vitro: TM-25659 (2, 10, 20, 100 μM) enhances nuclear TAZ localization in a dose-dependent manner and attenuates PPARγ-mediated adipocyte differentiation by facilitating PPARγ suppression activity of TAZ^[1].

TM-25659 (2, 10, 50 μM) enhances osteogenic gene expression and thereby increases osteoblast differentiation^[1].

In Vivo: TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone loss in vivo and decreases weight gain in an obesity model^[1].

TM-25659 has a favourable pharmacokinetic profile in rats. The plasma concentration of TM-25659 declines with an approximate t_1/2 of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L×h^-1×kg^-1 and the volume of distribution at steady-state (1.91 L×h^-1×kg^-1) is larger than the volume of total body fluids^[1].